Correlation Between Korean Drug and Korea Ratings

Can any of the company-specific risk be diversified away by investing in both Korean Drug and Korea Ratings at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Korean Drug and Korea Ratings into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Korean Drug Co and Korea Ratings Co, you can compare the effects of market volatilities on Korean Drug and Korea Ratings and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Korean Drug with a short position of Korea Ratings. Check out your portfolio center. Please also check ongoing floating volatility patterns of Korean Drug and Korea Ratings.

Diversification Opportunities for Korean Drug and Korea Ratings

-0.78

Correlation Coefficient

Korean Drug  Korea Ratings

Pay attention - limited upside

The 3 months correlation between Korean and Korea is -0.78. Overlapping area represents the amount of risk that can be diversified away by holding Korean Drug Co and Korea Ratings Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Korea Ratings and Korean Drug is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Korean Drug Co are associated (or correlated) with Korea Ratings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Korea Ratings has no effect on the direction of Korean Drug i.e., Korean Drug and Korea Ratings go up and down completely randomly.

Pair Corralation between Korean Drug and Korea Ratings

Assuming the 90 days trading horizon Korean Drug Co is expected to under-perform the Korea Ratings. In addition to that, Korean Drug is 1.97 times more volatile than Korea Ratings Co. It trades about -0.13 of its total potential returns per unit of risk. Korea Ratings Co is currently generating about 0.21 per unit of volatility. If you would invest  8,500,000  in Korea Ratings Co on September 14, 2024 and sell it today you would earn a total of  320,000  from holding Korea Ratings Co or generate 3.76% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Korean Drug Co  vs.  Korea Ratings Co

Korean Drug

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Korean Drug Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Korea Ratings

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Korea Ratings Co are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Korea Ratings is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Korean Drug and Korea Ratings

The main advantage of trading using opposite Korean Drug and Korea Ratings positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Korean Drug position performs unexpectedly, Korea Ratings can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Korea Ratings will offset losses from the drop in Korea Ratings' long position.

The idea behind Korean Drug Co and Korea Ratings Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.